283 related articles for article (PubMed ID: 11086023)
1. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones.
Chao L; Marcus-Samuels B; Mason MM; Moitra J; Vinson C; Arioglu E; Gavrilova O; Reitman ML
J Clin Invest; 2000 Nov; 106(10):1221-8. PubMed ID: 11086023
[TBL] [Abstract][Full Text] [Related]
2. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass.
Gavrilova O; Haluzik M; Matsusue K; Cutson JJ; Johnson L; Dietz KR; Nicol CJ; Vinson C; Gonzalez FJ; Reitman ML
J Biol Chem; 2003 Sep; 278(36):34268-76. PubMed ID: 12805374
[TBL] [Abstract][Full Text] [Related]
3. Troglitazone action is independent of adipose tissue.
Burant CF; Sreenan S; Hirano K; Tai TA; Lohmiller J; Lukens J; Davidson NO; Ross S; Graves RA
J Clin Invest; 1997 Dec; 100(11):2900-8. PubMed ID: 9389757
[TBL] [Abstract][Full Text] [Related]
4. Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones.
Bedoucha M; Atzpodien E; Boelsterli UA
J Hepatol; 2001 Jul; 35(1):17-23. PubMed ID: 11495036
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the liver of obese diabetic mice.
Memon RA; Tecott LH; Nonogaki K; Beigneux A; Moser AH; Grunfeld C; Feingold KR
Endocrinology; 2000 Nov; 141(11):4021-31. PubMed ID: 11089532
[TBL] [Abstract][Full Text] [Related]
6. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats.
Fujiwara T; Yoshioka S; Yoshioka T; Ushiyama I; Horikoshi H
Diabetes; 1988 Nov; 37(11):1549-58. PubMed ID: 3053303
[TBL] [Abstract][Full Text] [Related]
7. The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice.
Shimaya A; Kurosaki E; Nakano R; Hirayama R; Shibasaki M; Shikama H
Metabolism; 2000 Mar; 49(3):411-7. PubMed ID: 10726922
[TBL] [Abstract][Full Text] [Related]
8. Troglitazone and related compounds: therapeutic potential beyond diabetes.
Fujiwara T; Horikoshi H
Life Sci; 2000 Oct; 67(20):2405-16. PubMed ID: 11065164
[TBL] [Abstract][Full Text] [Related]
9. From fat-free mice, the skinny on diabetes.
Gura T
Science; 1998 Oct; 282(5389):604. PubMed ID: 9841407
[No Abstract] [Full Text] [Related]
10. Insulin resistance and its treatment by thiazolidinediones.
Lebovitz HE; Banerji MA
Recent Prog Horm Res; 2001; 56():265-94. PubMed ID: 11237217
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes.
Arioglu E; Duncan-Morin J; Sebring N; Rother KI; Gottlieb N; Lieberman J; Herion D; Kleiner DE; Reynolds J; Premkumar A; Sumner AE; Hoofnagle J; Reitman ML; Taylor SI
Ann Intern Med; 2000 Aug; 133(4):263-74. PubMed ID: 10929166
[TBL] [Abstract][Full Text] [Related]
12. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats.
Okuno A; Tamemoto H; Tobe K; Ueki K; Mori Y; Iwamoto K; Umesono K; Akanuma Y; Fujiwara T; Horikoshi H; Yazaki Y; Kadowaki T
J Clin Invest; 1998 Mar; 101(6):1354-61. PubMed ID: 9502777
[TBL] [Abstract][Full Text] [Related]
13. Novel genes regulated by the insulin sensitizer rosiglitazone during adipocyte differentiation.
Albrektsen T; Frederiksen KS; Holmes WE; Boel E; Taylor K; Fleckner J
Diabetes; 2002 Apr; 51(4):1042-51. PubMed ID: 11916924
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents.
Singh Ahuja H; Liu S; Crombie DL; Boehm M; Leibowitz MD; Heyman RA; Depre C; Nagy L; Tontonoz P; Davies PJ
Mol Pharmacol; 2001 Apr; 59(4):765-73. PubMed ID: 11259621
[TBL] [Abstract][Full Text] [Related]
15. A new thiazolidinedione, NC-2100, which is a weak PPAR-gamma activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice.
Fukui Y; Masui S; Osada S; Umesono K; Motojima K
Diabetes; 2000 May; 49(5):759-67. PubMed ID: 10905484
[TBL] [Abstract][Full Text] [Related]
16. Lipoatrophy, lipodystrophy, and insulin resistance.
Ganda OP
Ann Intern Med; 2000 Aug; 133(4):304-6. PubMed ID: 10929174
[No Abstract] [Full Text] [Related]
17. Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone.
Camp HS; Li O; Wise SC; Hong YH; Frankowski CL; Shen X; Vanbogelen R; Leff T
Diabetes; 2000 Apr; 49(4):539-47. PubMed ID: 10871190
[TBL] [Abstract][Full Text] [Related]
18. WY14,643, a peroxisome proliferator-activated receptor alpha (PPARalpha ) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice.
Chou CJ; Haluzik M; Gregory C; Dietz KR; Vinson C; Gavrilova O; Reitman ML
J Biol Chem; 2002 Jul; 277(27):24484-9. PubMed ID: 11994294
[TBL] [Abstract][Full Text] [Related]
19. [Thiazolidinediones: clinical data and perspectives].
Blicklé JF
Diabetes Metab; 2001 Apr; 27(2 Pt 2):279-85. PubMed ID: 11452222
[TBL] [Abstract][Full Text] [Related]
20. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL.
Chen Z; Ishibashi S; Perrey S; Osuga Ji ; Gotoda T; Kitamine T; Tamura Y; Okazaki H; Yahagi N; Iizuka Y; Shionoiri F; Ohashi K; Harada K; Shimano H; Nagai R; Yamada N
Arterioscler Thromb Vasc Biol; 2001 Mar; 21(3):372-7. PubMed ID: 11231916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
